Laropiprant + Placebo for Laropiprant

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rosacea

Conditions

Rosacea

Trial Timeline

Nov 1, 2011 → Apr 1, 2012

About Laropiprant + Placebo for Laropiprant

Laropiprant + Placebo for Laropiprant is a phase 1 stage product being developed by Merck for Rosacea. The current trial status is completed. This product is registered under clinical trial identifier NCT01451619. Target conditions include Rosacea.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01451619Phase 1Completed